Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tisotumab vedotin - Genmab/Seagen

Drug Profile

Tisotumab vedotin - Genmab/Seagen

Alternative Names: HuMax-TF; HuMax-TF-ADC; Humax®-TF-ADC; TF-011-MMAE; Tisotumab vedotin-tftv - Genmab/Seagen; TIVDAK

Latest Information Update: 07 Jun 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Genmab
  • Developer Genmab; Seagen; ZAI Lab
  • Class Antineoplastics; Auristatins; Drug conjugates; Immunotherapies; Immunotoxins; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Mitosis inhibitors; Tubulin polymerisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Cervical cancer
  • Phase II Fallopian tube cancer; Ovarian cancer; Peritoneal cancer; Solid tumours

Most Recent Events

  • 03 Jun 2024 Efficacy and adverse events data from a phase II trial in Solid tumours released by Genmab
  • 29 Apr 2024 Updated adverse events data from the phase II innovaTV 204 trial in Cervical cancer released by Genmab
  • 29 Apr 2024 Updated adverse events data from the phase III InnovaTV 301 trial in Cervical cancer released by Genmab
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top